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Introduction: Clinical responses to immune checkpoint blockade 
by anti-programmed cell death protein-1 (PD-1)/PD-L1 monoclonal 
antibodies in non–small-cell lung cancer (NSCLC) are associated 
with PD-L1 expression and smoking status. We aimed to determine 
the expression proﬁle of PD-1 and its ligands, PD-L1 and PD-L2, 
in both smokers and never smokers patients with KRAS-mutant 
NSCLC.
Methods: We retrospectively analyzed the clinical and molecular 
characteristics of 114 KRAS-mutant NSCLC patients (84 smok-
ers and 30 never smokers) and their clinical tumor samples for the 
expression of PD-1, PD-L1, and PD-L2 by immunohistochemistry 
(IHC). We used murine monoclonal antibodies anti-PD-L1 (clone 
9A11) and anti-PD-L2 (clone 9E5) to examine for tumor cell expres-
sion (0, negative; 1, weak; 2, moderate; 3, intense) and anti-PD-1 
(clone EH33) for tumor-inﬁltrating lymphocytes.
Results: PD-L1 expression was detected in 27 of 114 patients (24%; 
95% conﬁdence interval [CI], 16–33%) and associated with smoking 
status (current smokers, 44%; former smokers, 20%; never smokers, 
13%; p = 0.03). Higher intensity of PD-L1 expression (IHC-2+/IHC-
3+) was more frequently observed in smokers and associated with 
more pack-years. PD-L2 was positive in 54 of 114 patients (47%; 
95% CI, 38–57%) and not related to smoking status. PD-1–positive 
tumor-inﬁltrating lymphocytes were present in 77 of 114 tumor spec-
imens tested (68%; 95% CI, 59–77%) including 21 of 27 samples 
with PD-L1 expression and 39 of 54 samples with PD-L2–positive 
expression. We found that PD-L1 expression fades with the age of the 
specimens used for analyses decreasing beyond 3 years (p = 0.016).
Conclusions: The expression of PD-1 and its ligands PD-L1 and 
PD-L2 is heterogeneous within KRAS-mutant NSCLC and suggests 
an inducible expression of PD-L1 by smoking.
Key Words: PD-1, PD-L1, PD-L2, KRAS mutation, Lung cancer, 
Cancer immunotherapy.
(J Thorac Oncol. 2015;10: 1726–1735)
T-cell exhaustion limits optimal tumor control after chronic tumor antigen exposure, and this process results from 
upregulation of inhibitory receptors at the immune checkpoint 
after T-cell activation. Programmed cell death protein-1 (PD-1) 
is an inhibitory cell-surface receptor that is expressed by 
T-cells, B-cells, natural-killer cells, monocytes, and dendritic 
cells.1 The effector functions of T-cells that express PD-1 in 
the tumor microenvironment can be downregulated upon 
activation by PD-L1 (B7-H1) or PD-L2 (B7-DC), which are 
expressed by the tumor cells. PD-L1 is widely expressed by 
hematopoietic, nonhematopoietic, and tumor cells, whereas 
PD-L2 is expressed mainly by dendritic cells and macro-
phages.1 Therapeutic blockade of the PD-1 immune check-
point axis includes monoclonal antibodies (mAbs) against 
PD-1 and PD-L1.2,3 The use of mAbs to block either PD-1 
or PD-L1 prevents the downregulation of T-cell effector func-
tion, allowing T-cells to mediate tumor cell death.
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Clinical responses to anti-PD-1/PD-L1 mAbs have been 
observed in approximately 20% of non–small-cell lung can-
cer (NSCLC) patients in clinical trials, including some long-
term durable responses.3 Preliminary data from these studies 
suggest a relationship between PD-L1 tumor expression and 
clinical response. In a phase I clinical trial of nivolumab (BMS-
936558) involving 296 patients with advanced solid tumors (of 
which 122 were NSCLC), 42 patients had tumor specimens 
evaluable for PD-L1 expression: none of the 17 patients with 
PD-L1–negative tumors responded to therapy, whereas 9 of 
25 patients (36%) with PD-L1–positive tumors had an objec-
tive response.4 Moreover, objective responses have been more 
frequently observed in ever smokers compared with never 
smokers. Treatment with the anti-PD-L1 mAb MPDL3280A 
led to a response rate of 26% (11 of 43 patients) in current/
former smokers compared with 10% in never smokers (1 of 
10 patients).5 In this trial, as with nivolumab, PD-L1 expres-
sion was associated with higher response rate: 83% responses 
observed in the group with intense PD-L1 expression (immu-
nohistochemistry-3+, IHC-3+) compared with the overall 
23% response rate for the overall population.
The incidence of PD-L1 expression in NSCLC ranges 
from 20% to 50% in both squamous and nonsquamous his-
tologies but little is known in genomically deﬁned subsets of 
NSCLC.6–9 In preclinical models of epidermal growth factor 
receptor (EGFR) mutant lung cancer, EGFR pathway activa-
tion induced PD-L1 expression associated with a signature of 
immunosuppression that contribute to immune escape tumor 
pathogenesis.10
KRAS mutations are the most common oncogenic 
alteration in lung adenocarcinoma and have been detected in 
approximately 30% of smokers and approximately 10% of 
never smokers in Caucasian patients.11–13 Targeted therapies 
have been largely unsuccessful for the treatment of KRAS-
mutant NSCLC patients14,15 and therefore, there is a need to 
identify new therapeutic approaches for this group of patients. 
The incidence of the expression of PD-1 and its ligands, 
PD-L1 and PD-L2, is currently not deﬁned in this subset of 
tumors. Moreover, given that KRAS mutations are detected in 
both smokers and never smokers with lung cancer, it will be 
important to understand the relationship between the speciﬁc 
KRAS mutation subtype, smoking history and expression of 
PD-1 and its ligands.
In this study, we evaluated the expression of PD-1, 
PD-L1, and PD-L2 in KRAS-mutant tumors from both smok-
ers and never smokers. We also explored the association with 
both the speciﬁc KRAS mutations and smoking history. Our 
ﬁndings may help identify clinical features of KRAS-mutant 
patients to be enrolled in clinical trials of anti-PD-1 or PD-L1 
therapies.
MATERIALS AND METHODS
Study Population
Between August 2008 and January 2014, we identiﬁed 
514 KRAS-mutant NSCLC patients from 1818 patients who 
had undergone systematic tumor genotyping at Dana–Farber 
Cancer Institute as previously described.16,17 Forty-two of the 
KRAS-mutant patients were never smokers (<100 cigarettes/life-
time). We retrieved archival formalin-ﬁxed, parafﬁn-embedded 
(FFPE) tumor specimens from KRAS-mutant never smokers and 
current/former smokers. From the original list of 42 never smok-
ers, tissue could not be collected in 12 patients (tumor block 
exhausted/not located = eight patients, absence of consent = two 
patients, conﬁrmed remote story of smoking = two patients). The 
presence of tumor cells within each specimen was conﬁrmed by 
a pathologist (L.S.). The speciﬁc KRAS mutations were assessed 
locally in a Clinical Laboratory Improvement Amendments 
(CLIA)-certiﬁed lab as part of routine clinical genotyping.17 
All patients were consented to an institutional review board–
approved protocol allowing collection specimens and clinical 
data. Included in the protocol, all the patients completed a sur-
vey at baseline that included a smoking history questionnaire. 
The questionnaire contained the following questions: Have you 
smoked more than 400 cigarettes in your life? How old were 
you when you started smoking cigarettes? Do you currently 
smoke cigarettes (within the past month)? What was the date 
that you stopped smoking cigarettes? Throughout the time that 
you smoked cigarettes, what is the average number of cigarettes 
per day that you smoked? Pack-years of smoking were deﬁned 
as (average number of cigarettes per day/20) × years smoking. 
Former smokers were deﬁned as those who had quit more than 1 
year since the time of diagnosis of lung cancer.
Immunohistochemistry for PD-1, PD-L1,  
PD-L2, and CD3
The expression of PD-L1, PD-L2, and PD-1 was evaluated 
in clinical FFPE tumor specimens using IHC. Four-micrometer 
thick sections were deparafﬁnized, rehydrated, and heated in 
a steamer for 30 minutes for antigen retrieval in citrate buffer 
pH 6.0 (PD-1 and PD-L2) or ethylenediaminetetraacetic acid 
(EDTA) buffer pH 8.0 (PD-L1; Invitrogen, Carlsbad, CA). After 
cooling for 20 minutes, sections were incubated with peroxidase 
block (DAKO, Carpinteria, CA) for 5 minutes, and serum-free 
protein block (DAKO) for 20 minutes. Slides were then incu-
bated at room temperature for 1 hour with primary antibodies 
against PD-1 (1:1000), PD-L1 (1:200), or PD-L2 (1:10,000), 
respectively, diluted in Da Vinci green diluent (Biocare Medical, 
Concord, CA). Anti-PD-1 (clone EH33), anti-PD-L1 (clone 
9A11), and anti-PD-L2 (clone 366C.9E5) antibodies are 
mouse mAbs and obtained from Gordon Freeman’s laboratory, 
Dana–Farber Cancer Institute. All these antibodies have been 
previously validated.18–21 For the secondary antibody, Envision 
anti-mouse HRP-labeled polymer (DAKO) was applied to the 
sections for PD-1 or PD-L1 staining whereas PowerVision 
poly-horseradish peroxidase (HRP) anti-mouse (PV6114, Leica 
microsystems, Buffalo Grove, IL) was used for PD-L2 stain-
ing for 30 minutes. A subset of cases was also stained for CD3 
(DAKO, A0452, dilution 1:250), which was performed by Leica 
Bond automated immunostainer (Leica), using a standard proto-
col. The slides were developed with diaminobenzidine (DAKO), 
counterstained with hematoxylin, dehydrated, and mounted. 
Normal human tonsil tissue was used as a positive control for 
PD-1, PD-L1, and CD3 staining. For PD-L2, known positive 
tumor slides were used as positive controls. Negative controls 
were included in each panel of staining for all markers.
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Staining Interpretation
PD-L1 expression was considered positive if greater 
than or equal to 5% of tumor cells had membranous staining, as 
used previously.4 PD-L2 expression was considered positive if 
greater than or equal to 10% of tumor cells had immunoreac-
tivity. The intensity (0, negative; 1+, weak; 2+, moderate; 3+, 
intense) and the percentage of positive-stained tumor cells for 
these two antibodies were assessed (Fig. 1). Immunoreactivity 
for PD-1 and CD3 was detected in the tumor-inﬁltrating lym-
phocytes (TILs). Positive TIL cells were counted under 20× 
middle power ﬁeld (Fig. 1). For each slide, ﬁve representative 
areas were chosen to count the positive TILs, and the average 
absolute number was recorded. All the slides were evaluated 
and scored by a pathologist (X.L.) blinded to clinical data. 
The scoring for each marker was performed at least twice with 
1-week interval.
Statistical Analysis
Associations between categorical data were tested using 
Fisher’s exact test; Kruskal–Wallis test was used to test for 
association with continuous measures. All tests were con-
ducted at the two-sided 0.05-level, and no adjustments have 
been made for multiple comparisons.
RESULTS
Patient Characteristics
We analyzed PD-L1 and PD-L2 expression in cancer 
cells and PD-1 expression in TILs by IHC in FFPE tumor spec-
imens in 114 KRAS-mutant NSCLC patients (current/former 
smokers, 84; never smokers, 30). There were no imbalances 
in clinical or molecular characteristics when comparing those 
selected for analyses to those that were not selected from the 
original list of KRAS-mutant patients (Supplementary Table 1, 
Supplementary Digital Content 1, http://links.lww.com/
JTO/A902). The patient demographics of the selected cases 
are summarized in Supplementary Table 2 (Supplementary 
Digital Content 2, http://links.lww.com/JTO/A903. Current/
former smoker and never smoker patients were similar in age, 
gender, race, histology, and stage. The different and distinctive 
prolife of KRAS mutations between smokers and never smok-
ers was similar to previous studies.12,22
Ninety-three of 114 tumor specimens analyzed for 
PD-L1, PD-L2, and PD-1 expressions (82%) underwent 
biopsy at the time of the diagnosis of the disease and did not 
receive interval treatments. Hence, the vast majority of KRAS-
mutant specimens included in our series was not influenced 
by previous treatments and therefore would be considered as 
baseline levels on PD-L1 and PD-L2 expressions.
PD-L1 Expression by Patient Characteristics
PD-L1 expression was shown by IHC in 27 of 
114 patients (24%; 95% conﬁdence interval [CI], 16–33%). 
Smokers appeared to demonstrate increased incidence of 
PD-L1 expression (current smokers, 44%; former smokers, 
20%; never smokers, 13%; p = 0.03; Fig. 2A) and also trend 
toward higher intensity of PD-L1 expression (p = 0.03; 
Fig. 2B). Moreover, the intensity of PD-L1 expression was 
also associated to higher number of pack-years of smoking, 
as patients with IHC-2+/3+ PD-L1 expression had a median 
of 34 pack-years of smoking compared with 20 pack-years 
in the group of patients with PD-L1 IHC-0/1+ (p = 0.015; 
Fig. 2C). Considering the 27 PD-L1–positive cases in our 
series, PD-L1 was expressed in 5% to 20% of tumor cells in 
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fIGURE 1. Programmed death-
ligand 1 (PD-L1), PD-L2, and 
programmed cell death protein 1 
(PD-1) expression in formalin-fixed, 
paraffin-embedded (FFPE) samples 
of KRAS-mutant lung cancer. Lung 
adenocarcinoma specimens show-
ing different PD-L1 and PD-L2 
intensities of expression in tumor 
cells and PD-1 expression in tumor-
infiltrating lymphocytes (1+, weak; 
2+, moderate; 3+, intense). Samples 
stained with anti-PD-L1 antibody 
(clone 9A11), anti-PD-L2 (clone 
9E5), and anti-PD-1 (clone EH33). 
Scale bar, 100 μm.
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ﬁve cases (IHC-1+, n = 2; IHC-2+, n = 2; IHC-3+, n = 1), 
more than 20% to 50% of tumor cells in ﬁve cases (IHC-1+, 
n = 1; IHC-2+, n = 1; IHC-3+, n = 3), and more than 50% 
of tumor cells in 17 cases (IHC-1+, n = 0; IHC-2+, n = 4; 
IHC-3+, n = 13). Median percentage of PD-L1 expression 
in tumor cells was not different among ever smokers and 
never smokers with PD-L1–positive expression (70% vs. 
55%, respectively; p = 0.92).
There were no differences in PD-L1 expression by age, 
gender, race, histology, type of KRAS mutation (transver-
sion versus transition), or speciﬁc KRAS mutation (Table 1). 
Patients with stage IV disease had higher PD-L1 expression 
compared with earlier disease stages (stage IV 33% versus 
stages I–III 15%; p = 0.046). There was a trend to differential 
expression on PD-L1 by organ site but the limited number of 
cases per site did not allow for further conclusions (Table 1). 
Brain metastases showed PD-L1–positive expression in only 
1 of 7 cases (14%), whereas in malignant pleural effusions, 
PD-L1 expression was observed in 5 of 12 cases (42%).
PD-L1 Expression by Biopsy Characteristics
We next analyzed whether PD-L1 expression differed 
based on the type of tumor biopsy (Table 1). The specimens 
in our series included 85 surgical specimens (75%), 18 core 
biopsies or transbronchial biopsies (16%), and 11 cytology 
specimens (10%). PD-L1 expression was similar regardless 
of the type of biopsy used for the IHC analyses (p = 0.465).
We also evaluated the age of the tumor specimen 
and whether this had an impact on PD-L1 positivity. More 
recent tumor specimens had a higher PD-L1 expression 
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fIGURE 2. Programmed death-ligand 1 (PD-L1) expression in KRAS-mutant non–small-cell lung cancer (NSCLC) and associa-
tion with smoking status. A, PD-L1 expression is detected in current smokers (44%), former smokers (20%), and never smok-
ers (13%); n = 114, p = 0.03. B, Higher intensity of PD-L1 expression (IHC-2+/3+) was more frequently observed in smokers 
(specially in current smokers), whereas weak or negative expression was more frequent in never smokers. C, More intense PD-L1 
expression (immunohistochemistry [IHC]-2+/3+) is associated to more pack-years of smoking (34 pack-years compared with 20 
pack-years in the group of patients with PD-L1 IHC-0/1+, p = 0.015); D, PD-L1 expression fades with the age of formalin-fixed, 
paraffin-embedded (FFPE) tumor blocks, particularly in older than 3 years since specimen collection.
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TABLE 1. PD-L1 and PD-L2 Expression in KRAS-Mutant NSCLC (n = 114)
Characteristic PD-L1 Positive PD-L1 Negative P Value PD-L2 Positive PD-L2 Negative P Value
Overall, n (%) 27 (24) 87 (76) 0.617 54 (47) 60 (53)
0.557Age, median (yr) 65 (42–77) 63 (20–84) 63.5 (20–83) 63 (36–84)
Gender, n (%)
  Female 17 (63) 63 (72) 0.348 39 (72) 41 (68) 0.686
  Male 10 (37) 24 (28) 15 (28) 19 (32)
Smoking status, n (%) 
  Former/current 23 (85) 61 (70) 0.141 36 (67) 48 (80) 0.137
  Never smoker 4 (15) 26 (30) 18 (33) 12 (20)
Race, n (%) 
  Caucasian 23 (85) 81 (93) 0.259 46 (85) 58 (97) 0.088
  Asian 1 (4) 1 (1) 1 (2) 1 (2)
  African American 2 (7) 4 (5) 5 (9) 1 (2)
  Hispanic 0 (0) 0 (0) 0 (0) 0 (0)
  Declined/unknown 1 (4) 1 (1) 2 (4) 0 (0)
Histology, n (%) 
  Adenocarcinoma 24 (89) 80 (92) 0.576 50 (93) 54 (90) 1
  Squamous 0 (0) 0 (0) 0 (0) 0 (0)
  Adenosquamous 1 (4) 2 (2) 1 (2) 2 (3)
  Large cell 0 (0) 0 (0) 0 (0) 0 (0)
  NOS 2 (7) 5 (6) 3 (6) 4 (7)
Stage, n (%)
  I–III 9 (33) 50 (57) 0.046 33 (61) 26 (43) 0.064
  IV 18 (67) 37 (43) 21 (39) 34 (57)
KRAS mutation, n (%)
  G12C 8 (30) 27 (31) 0.824 15 (28) 20 (33) 0.762
  G12V 4 (15) 14 (16) 8 (15) 10 (17)
  G12D 7 (26) 25 (29) 16 (30) 16 (27)
  G13X 1 (4) 2 (2) 2 (4) 1 (2)
  Q61H 2 (7) 4 (5) 3 (6) 3 (5)
  Multiple 0 (0) 5 (6) 1 (2) 4 (7)
  Others 5 (19) 10 (11) 9 (17) 6 (10)
Class of KRAS mutation, n (%)
  Transversion 20 (74) 59 (68) 0.637 35 (65) 44 (73) 0.417
  Transition 7 (26) 28 (32) 19 (35) 16 (27)
Biopsy type, n (%)
  Surgical 18 (67) 67 (77) 0.465 41 (76) 44 (73) 0.680
  Core/bronchial 6 (22) 12 (14) 7 (13) 11 (18)
  Citology/FNA 3 (11) 8 (9) 6 (11) 5 (8)
Tissue of origin, n (%)
  Lung 14 (52) 55 (63) 0.51 36 (67) 33 (55) 0.61
  Brain 1 (4) 6 (7) 4 (7) 3 (5)
  Pleura 5 (19) 7 (8) 4 (7) 8 (13)
  Lymph node 3 (11) 10 (11) 5 (9) 8 (13)
  Others 4 (15) 9 (10) 5 (9) 8 (13)
Sample age (year of collection), n (%)
  <2008 2 (7) 11 (13) 0.016 7 (13) 6 (10) 0.438
  2008–2010 9 (33) 51 (59) 25 (46) 35 (58)
  2011–2013 16 (59) 25 (29) 22 (41) 19 (32)
PD, programmed cell death protein; NSCLC, non–small-cell lung cancer; FNA, ﬁne-needle aspiration.
G13X includes G13C (n = 2) and G13D (n = 1) mutations.
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compared with those collected earlier (year of collection 
before 2008, 15%; 2008–2010, 15%; 2011–2013, 39%; 
p = 0.016; Table 1, Fig. 2D).
PD-L2 Expression and Association 
with PD-L1 Expression
PD-L2 expression was present in 54 of 114 patients 
(47%; 95% CI, 38–57%) and did not seem to be associ-
ated with smoking status (p = 0.24; Supplementary Fig. 1, 
Supplementary Digital Content 3, http://links.lww.com/JTO/
A904). There were no differences in PD-L2 expression by age, 
gender, race, histology, type of KRAS mutation (transversion 
versus transition), or the speciﬁc KRAS mutation (Table 1). 
Patients with stages I to III disease had a nonsigniﬁcant trend 
to higher PD-L2 expression compare with stage IV disease. 
There was no difference on PD-L2 expression by site of dis-
ease. Notably, PD-L2 was expressed in tumor cells in four of 
seven (57%) brain metastasis. PD-L2 expression was similar 
regardless of the type of biopsy (p = 0.68) and did not vary by 
the age of the tumor specimen (p = 0.44; Table 1).
There was no association between PD-L1 and PD-L2–
positive cases. The intensity of expression between PD-L1 and 
PD-L2 was also not associated (p = 0.24). Of note, nearly half 
of the PD-L1–negative cases showed PD-L2–positive expres-
sion (Fig. 3B). In total, 12% of patients had PD-L1 expres-
sion only, 36% PD-L2 expression only, and 11% both PD-L1 
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tumor cells. Some immune cells in the tumor stroma show immunoreactivity to PD-L1 and PD-L2, probably indicating antigen 
trafficking.
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and PD-L2–positive expression. Alterations in the tumor sup-
pressor LKB1/STK11 have been related to an “immune-inert” 
state, including low PD-L1 expression, when occurring in 
KRAS-mutant lung adenocarcinoma. We have previously vali-
dated an IHC assay to test for liver kinase B1 (LKB1) status 
in KRAS-mutant adenocarcinoma.23 We used the same series 
of cases than in our work for PD-1 axis expression. We have 
used these results to look for any association of PD-L1/PD-L2 
expression and LKB1 status. We found that LKB1 was lost in 
33 cases out of 113 cases tested (one case was not consider-
ing for LKB1 because of a fail of staining). Overall, PD-L1 
and PD-L2 were more frequently expressed when LKB1 was 
intact, although this difference was statistically signiﬁcant 
only for PD-L2 cases. Only 5 of 27 PD-L1–positive cases 
occurred in samples with LKB1 loss (p = 0.23), and only in 8 
of 54 PD-L2–positive cases (p = 0.002).
PD-1 Expression and Association 
with PD-L1/PD-L2
PD-1–positive TILs were present in 77 of 114 tumor 
specimens tested (68%; CI 95%, 59%-77%). To analyze the 
association on PD-1–positive cells with the presence of CD3+ 
TILs, we selected 20 samples grouped by increasing number 
of PD-1 cells (0, 1–20, 20–50, and >50). Cells that were PD-1 
positive tended to also be CD3+ cells (Kruskal–Wallis test 
p = 0.0052; Fig. 3A).
PD-1–positive TILs were found in 21 of 27 samples 
with PD-L1 expression (median, 12 counts; range, 2–250) and 
39 of 54 samples with PD-L2–positive expression (median, 6 
counts; range, 1–150). Nevertheless, the presence of PD-1–
positive TILs was not associated with either with PD-L1 or 
PD-L2 expression (p = 0.24 or p = 0.33) or to smoking status 
or type or class of KRAS mutation (data not shown).
We did not ﬁnd any association between the median 
number of PD-1–positive TILs and PD-L1 or PD-L2 inten-
sity of expression (p = 0.06 and p = 0.08, respectively; Fig. 
3A). However, we observed a nonsigniﬁcant trend toward 
higher number of PD-1–positive TILs in samples with lev-
els of PD-L1 IHC-3+ (Fig. 3A). More speciﬁcally, in a sub-
group of four patients with intense immune inﬁltration 
(>50 PD-1–positive TILs), we observed concomitant PD-L1 
IHC-3+ expressed in 70% to 90% of tumor cells, also associ-
ated with negative PD-L2 expression (Fig. 3C).
Collectively, several combinations of PD-1 expression 
with or without concomitant PD-L1 or PD-L2 expression 
were observed (Fig. 3B). Of these, the concomitant expression 
of PD-1 with PD-L2 and expression of PD-1 alone were the 
most common groups observed, with a 25% incidence each.
PD-L1 Expression in Stromal Immune Cells
We looked for the expression of PD-L1 in tumor-inﬁl-
trating immune cells. There were seven cases with no available 
results. A total of 15% of cases revealed no PD-L1 staining in 
immune cells. A weak staining, considered as less than 5% 
was present in 55% of cases. A marked staining, considered 
as more than 5% was present in 30% of cases. Any PD-L1 
staining in tumor cells was observed irrespectively of PD-L1 
expression in immune cells. Absence of PD-L1 expression 
in immune cells was frequently found with lower number 
of PD-1–positive cells (p = 0.014), but only PD-L1 expres-
sion more than 10% in immune cells was associated to higher 
number of PD-1 positive (p = 0.039). An example of adaptive 
immune resistance (PD-L1 IHC-3+ in tumor cells with high 
number of PD-1–positive inﬁltrating cells) with PD-L1 and 
PD-L2 immunoreactivity in stromal immune cells can be seen 
in Fig. 3C.
DISCUSSION
KRAS-mutant NSCLC is the largest genomically deﬁned 
subset of NSCLC and for which new therapies are needed. 
PD-1 immune checkpoint inhibitors may represent a thera-
peutic opportunity for KRAS-mutant lung cancer patients. We 
evaluated the expression of PD-1, PD-L1, and PD-L2, spe-
ciﬁcally in KRAS-mutant NSCLC to identify features within 
this subset of lung cancer that may correlate with the expres-
sion of these proteins. Previous studies that analyzed PD-L1 
expression in NSCLC patients did not report on the genotype 
on the tumors or only included surgically resected early-stage 
tumors, with limited number of KRAS-mutant cases.7–9,24–27
We report on three new antibodies against PD-L1 
(clone 9A11), PD-L2 (clone 9E5), and PD-1 (clone EH33) 
optimized for IHC in clinical samples. These antibodies have 
been previously validated as detailed elsewhere.18–21 There is 
no consensus in the percentage of PD-L1 expression that is 
clinically meaningful as a predictive biomarker of efﬁcacy 
for the different immune checkpoint inhibitors in the clinic. 
For that reason, we adopted the same criterion for PD-L1 that 
was considered in the original work of Topalian et al.4 exam-
ining the safety and activity of nivolumab. PD-L2 expres-
sion in lung cancer is reported in limited number of NSCLC 
cases.9,27,28 mAbs to evaluate PD-L2 expression in epithelial 
cells have been recently incorporated. Also, the role of PD-L2 
in modulating tumor immunity is less clear than for PD-L1, 
and the predictive role to immune therapy is unknown. For 
these reasons, the optimal cutoff to deﬁne positivity of PD-L2 
on tumor cells is not deﬁned yet. We present the largest col-
lection of cases assessing for PD-L2 expression in a geneti-
cally deﬁned subset of lung adenocarcinoma harboring KRAS 
mutations. Compared with PD-L1, PD-L2 expression is both 
membranous and cytoplasmic. We assume a 10% cutoff to 
deﬁne positivity, as it is the most often used for cytoplasm 
and membrane IHC staining score in clinical diagnosis and 
research papers. In our work, the rate of positivity of PD-L2 
considering a 10% of tumor expression was 47% (54 of 114). 
There is no difference in the positivity rate considering a 5% 
cutoff in our series. By raising the cutoff to deﬁne positivity 
to 20% of tumor expression, instead of 10%, PD-L2 remained 
expressed in 41% (47 of 114) of samples (data not shown).
We observed a relatively low incidence of expression of 
PD-L1: 24% in KRAS-mutant adenocarcinoma compared with 
up to 50% of expression reported in the overall lung adenocar-
cinoma population.8,9,24–28 These differences may be because 
of methodological issues: different antibodies, the deﬁnition 
on positivity (limited to tumor cells or including stromal 
cells), and different cutoffs of expression used. Anti-PD-L1 
clone 5H1 antibody has been the most widely used to date. 
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We report on a new antibody, clone 9A11, with high sensitiv-
ity and speciﬁcity for IHC,19 but concordance between assays 
and validation of different cutoffs has not been addressed 
yet. Alternatively, it is possible that PD-L1 expression is not 
driven by KRAS mutation.
Our ﬁndings elucidate the relationship between a his-
tory of smoking and expression of PD-L1. The incidence of 
PD-L1 expression was correlated with exposure to tobacco 
and did incrementally from never smokers, former smokers 
to current smokers. In addition, higher expression levels on 
PD-L1, considered as IHC-2+ and IHC-3+, were more fre-
quently found in smokers and also with a more intense history 
of smoking as measured by pack-years. The biological expla-
nation for this ﬁnding is so far unknown and merits further 
investigation. The exposure to tobacco carcinogens may result 
in more highly mutated tumors, exposing more neoantigens 
in smokers than tumors from patients who are never smokers, 
resulting in higher PD-L1 expression.29,30 Furthermore, the 
inflammatory response induced by smoking involves T-cell 
proinflammatory cytokines, including interferon-γ (IFN-
γ) that is known to induce PD-L1 expression.31,32 Recently, 
higher neoantigen burden has been associated to improved 
clinical beneﬁt from anti-PD-1 therapies.30 Moreover, the 
preliminary higher responses observed in smokers with the 
anti-PD-L1 MPDL3280A and the anti-PD-1 pembrolizumab 
(MK-3475) may be explained on the basis of PD-L1 upregula-
tion by smoking.5,33 However, the relationship between smok-
ing and PD-L1 status might be confounded in different lung 
cancer genotypes other than KRAS, e.g., in EGFR mutant or 
anaplastic lymphoma kinase ALK translocated adenocarci-
noma, which is mostly found in never smokers patients, and 
for which PD-L1 expression can be genetically upregulated by 
mutant EGFR or ALK signaling, respectively.10,34
We observed a wide expression of PD-L2 in KRAS-
mutant lung adenocarcinoma. With almost half of the cases 
revealing a positive staining, it was nearly double than 
PD-L1. Interestingly, in all of the 54 positive cases in our 
series involved at least a 20% of positive-stained tumor cells. 
Contrary to PD-L1, PD-L2 expression was not found associ-
ated with smoking. Moreover, we did not ﬁnd any association 
between PD-L1 and PD-L2 expressions in our series of KRAS-
mutant lung cancer, as reported in other sets of tumors.28
PD-L2 has not received as much attention as PD-L1 in 
cancer until recently. Although both PD-L1 and PD-L2 are 
ligands of PD-1 and both downregulate T-cell effector func-
tion, these two ligands work in different manner.35 The locus 
containing both PD-L1 and PD-L2 genes are located in the 
same chromosome region (9p24.1). However, PD-L1 and 
PD-L2 exhibit distinct expression patterns and are differen-
tially regulated at the transcriptional level.36,37 For instance, 
PD-L1 expression is strongly induced by Th1 cytokine IFN-γ, 
whereas PD-L2 is only weakly induced.36 In contrast, 
PD-L2 transcription is regulated by IL4/IL13/STAT6 sig-
naling and has been related to a Th2 cytokine response.36 
PD-L2 seems to play an important role in the modulation of 
Th2 responses, resulting in cancer cell escape from immune 
surveillance.37 Smoking is known to cause a IFN-γ inflam-
mation, raising the hypothesis that PD-L1–positive tumors 
emerge in the setting of a Th1-type acute inflammation. It is 
possible that PD-L1 expression may predominate in tumors 
with a different inflammatory state than PD-L2-predominant 
tumors. This differential expression on PD-L1 and PD-L2 
has been recently found in certain tumor types and may have 
therapeutic implications.20,37 Anti-PD-1 therapies can block 
the interaction between either PD-L1 or PD-L2 and PD-1, 
whereas anti-PD-L1 antibodies leave PD-L2 free to inter-
act with PD-1, although PD-L2 expression did not seem 
to be associated with resistance to anti-PD-L1 antibody.3,38 
Therapeutic studies targeting PD-L2 could be of interest 
based in the high rates of PD-L2 expression observed in 
KRAS-mutant adenocarcinoma.
The heterogeneity of PD-L1 and PD-L2 expressions 
described is in consonance with the known biological het-
erogeneity of KRAS-mutant lung cancer. It has been recently 
described that co-occurring genomic alterations deﬁne major 
subsets of KRAS-mutant lung adenocarcinoma with distinct 
immune proﬁles.39 Interestingly, KRAS-mutant tumors har-
boring STK11/LKB1 alterations expressed lower levels of 
immune markers, including PD-L1, compared with those 
with TP53 alterations in which tumors demonstrated higher 
levels of inflammatory markers and immune checkpoint 
effector molecules.39 Although this was a secondary analysis, 
we compare the LKB1 status assessed by a validated IHC 
assay in our cohort of KRAS-mutant adenocarcinoma cases.23 
Overall, PD-L1 and PD-L2 were more frequently expressed 
when LKB1 was intact, although this difference was statisti-
cally signiﬁcant only for PD-L2 cases, probably because of 
the limited number of cases with PD-L1–positive expression 
to compare. It is possible that an intact LKB1/AMP-activated 
protein kinase or adenosine monophosphate-activated pro-
tein kinase (AMPK) pathway may be required to modulate 
PD-ligands’ expression as has been already proposed.39
Our study reveals heterogeneity in the immune microen-
vironment of KRAS-mutant lung adenocarcinoma. Cancers have 
been categorized into four different tumor microenvironments 
based on the presence of TILs and PD-L1 expression.40 They 
are type I (adaptive immune resistance) characterized by the 
presence of TILs and expression of PD-1 ligands in tumor cells; 
type II (immunologic ignorance) with absence of both TILs and 
PD-1 ligands; type III (intrinsic induction) displaying PD-1 
ligands expression in tumor cells but absence of TILs; and type 
IV (tolerance) with presence of TILs but lack of PD-1 ligands 
expression in tumor cells. In our work, we observed the pres-
ence of the four different tumor microenvironments described 
in the following proportion (Fig. 3B): type I in 43% of cases, 
type II in 16%, type III in 16%, and type IV in 25% of cases. 
This is the ﬁrst time that this immune heterogeneity is described 
in clinical samples of KRAS-mutant lung adenocarcinoma.
Immune heterogeneity in KRAS-mutant lung adeno-
carcinoma may have therapeutic implications. It has been 
suggested that T-cell inflamed tumors—characterized by 
the presence of regulatory immune cells, T-cell anergy, and 
expression of inhibitory factors—are more likely to derive 
beneﬁt for anti-PD-1/PD-L1 therapeutic interventions.30,41–43 
In addition, responses to MPDL3280a (anti-PD-L1) have 
been reported with tumors expressing high levels of PD-L1, 
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especially when PD-L1 was expressed by tumor-inﬁltrating 
immune cells across multiple cancer types.38 It has been 
suggested that MPDL3280A is most effective in patients 
in whom preexisting immunity is suppressed by PD-L1 and 
is re-invigorated on antibody treatment.38 We are limited to 
analyze these features because our results lack correlation 
with clinical outcomes to anti-PD-1/PD-L1 agents in our 
cases. Based on our observations, we propose the use of 
comprehensive immune diagnostic markers to better recapit-
ulate the immune landscape in lung cancer. The use of these 
panels may help to interpret the clinical results from immune 
checkpoint inhibitors in KRAS-mutant lung adenocarcinoma.
We also recognized the fading of PD-L1 expression in 
FFPE specimens with the age of the tumor block. This was 
especially signiﬁcant when samples were older than 3 years. 
This is probably a matter of antigen preservation in FFPE tumor 
blocks or sample selection bias that merits further conﬁrmation. 
We recommend to analyze contemporary biopsies when con-
sidering patients for anti-PD-1/PD-L1 therapies, rather than old 
archival specimens because is likely to yield a more accurate 
depiction of current PD-1, PD-L1, and PD-L2 status.
In summary, KRAS-mutant adenocarcinoma is a hetero-
geneous disease for PD-1 and its ligands PD-L1 and PD-L2 
and should be considered when analyzing the clinical out-
comes of patients treated with anti-PD-1/PD-L1 immune 
checkpoint inhibitors. We observed PD-L1 expression related 
to smoking status but not associated to speciﬁc KRAS muta-
tions, suggesting PD-L1 expression is not genetically driven 
by KRAS mutation but inducible by smoking. We propose the 
use of an immune diagnostic panel to better recapitulate the 
immune landscape of clinical samples in lung cancer and the 
use of contemporary biopsies to assess their status when con-
sidering PD-1 immune checkpoint inhibitors in NSCLC.
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